Adipose tissue is not an inert cell mass contributing only to the storage of fat, but a sophisticated ensemble of cellular components with highly specialized and complex functions. In addition to managing the most important energy reserve of the body, it secretes a multitude of soluble proteins called adipokines, which have beneficial or, alternatively, deleterious effects on the homeostasis of the whole body. The expression of these adipokines is an integrated response to various signals received from many organs, which depends heavily on the integrity and physiological status of the adipose tissue. One of the main regulators of gene expression in fat is the transcription factor peroxisome proliferatoractivated receptor g (PPARg), which is a fatty acid-and eicosanoid-dependent nuclear receptor that plays key roles in the development and maintenance of the adipose tissue. Furthermore, synthetic PPARg agonists are therapeutic agents used in the treatment of type 2 diabetes.
Introduction
In mammals, the ensemble of fat tissues constitutes a multi-depot adipose organ that is highly innervated and rich in blood vessels. It serves metabolic and endocrine functions, which are of critical importance for the integrative physiology of the body. This organ is not only composed of lipid-laden mature adipocytes and adipocyte precursors called preadipocytes, but also comprises a stromal vascular fraction (SVF), which includes blood cells, endothelial cells and macrophages. Although adipocytes have been recognized as secretory cells with endocrine functions for some time, the importance of macrophages and stromal vascular cells within the adipose tissue of obese animals and humans is now well accepted. This knowledge has contributed to a better understanding of the intense crosstalk between the different components of fat tissue, and has led to stimulating speculations about the initiation of pathological conditions. Furthermore, analysis of the sympathetic and parasympathetic innervations of adipose tissue revealed that the autonomic nervous system modulates the fat cell number and other processes, such as adipokine expression levels, lipogenesis/lipolysis, fatty acid uptake, and glucose uptake. These recent findings underscore the integrative role of the brain in long-term energy balance [1] . As part of this interactive and integrated network, the adipose tissue per se is involved in the coordination of diverse processes including not only energy metabolism but also endocrine and immune regulatory functions. This review underlines the importance of the functional integrity of the adipose tissue in maintaining health. Both adipose tissue deficiency (lipodystrophy, lipoatrophy) and adipose tissue excess (obesity) have deleterious effects and consti Figure 1 Schematic representation of the human adipose organ, main adipose subtypes and functions. The rodent perigonadal fat, which has no relevance in humans, is depicted here only as a reminder of its broad use as an experimental model of vis fat. Different processes and adipokine expression are indicated with respect to their prevalence in sc WAT or vis WAT. * enhances insulin sensitivity; ** enhances insulin resistance. Functions of WAT and their regulation by PPARg 488 npg constitutes the largest energy reservoir in mammals as a guard against times of food shortage. In contrast, BAT is highly specialized in non-shivering adaptive thermogenesis. Although the role of BAT in rodents and neonates of other mammalian species, including humans, has been extensively studied, the persistence and importance of BAT in adult humans is currently under intense investigation and putative functions remain to be elucidated [8, 9] . In brief, the BAT and WAT closely collaborate in partitioning the energy contained in lipids between thermogenesis and other metabolic functions, respectively. This review will concentrate on the latter only.
WAT subtypes
Mature adipose cells, whose differentiation is controlled by a cascade of specific transcription factors, represent the major component of the adipose tissue. During the differentiation process, morphologically and functionally diverse tissues give birth to the sc and vis adipose tissues [4, [10] [11] [12] [13] . Each of them has a different metabolic activity reflected in a different sensitivity to insulin [4, 14, 15] . Different expression profiles in sc and vis WAT of several genes involved in embryonic development and pattern specification suggest different genetically determined developmental programs in preadipocytes for the formation of each depot with its specific functional characteristics [16] . In addition to the main sc and vis depots, WAT is found in small amounts around other organs, such as the heart, kidney and genitalia.
Among these different tissues, the sc deposits are those that undergo the more conspicuous enlargements and retractions without noticeable effects on insulin sensitivity, glucose metabolism, and metabolic profile [17, 18] . In humans, the sc adipose tissue can be subdivided into two distinct layers: the superficial and the deep layers. There is a gender dimorphism in the amount of deep layer sc WAT. Fifty-one percent of a woman's sc WAT is found in this layer, whereas in a man it comprises 66% of the sc WAT. It appears that obesity is associated with a preferential increase in the deep layer, and weight loss in obese people also impacts more on the deep layer, suggesting that the deep layer is metabolically more active than the superficial one [19] .
The vis fat is found in both the intraperitoneal and retroperitoneal compartments. Intraperitoneal fat is itself composed of omental and mesenteric adipose tissues, and in rodents perigonadal (epididymal) adipose tissues, the latter being largely used as an experimental model for vis fat. The delimitation between the intraperitoneal and retroperitoneal fat is along the ventral surface of the kidney and the dorsal borderline of the intestines. In humans, the retroperitoneal fat is minor as it represents only 25% of the total vis part [15] . Vis fat is distinct from other adipose regions since it is drained by the portal vein, and therefore has a unique direct connection with the liver. Reduction of vis deposits promotes insulin sensitivity and glucose metabolism. In fact, vis fat mass correlates positively with glucose intolerance, alteration of plasma lipoprotein lipid levels, increased triglyceride (TG) and cholesterol concentrations, hypertension, and dyslipidemia [20, 21] . Moreover, insulin signaling analysis in human vis and sc fat shows that the vis adipose tissue expresses higher levels of specific insulin-signaling proteins and exhibits an earlier and greater response to insulin than the sc WAT [22] . In short, vis fat is more affected by weight reduction than sc fat, is more active metabolically, has a higher lipolytic rate, and produces more adipokines ( Figure 1 ) [15, 23] .
These different characteristics of the two fat depots with respect to morphological structure, metabolic activity, and hormonal control suggest a specific role distribution between vis and sc WAT in whole-body energy homeostasis and a differential impact on insulin sensitivity in skeletal muscle and liver. These functions will not be discussed further since the information is already available in two reviews [15, 24] .
WAT and energy homeostasis
One of the primary functions of WAT is to store excess energy as lipids, which are then mobilized to other tissues in response to metabolic needs during periods of food scarcity [9] .
After copious meals, and in periods of food abundance, the adipose tissue stores the energy ingested in excess as TG (Figure 2A) . The adipocyte is able to accumulate astonishingly high amounts of TG, which can be stored anhydrously within intracellular lipid droplets coated with proteins called perilipins, without causing cellular lipotoxicity [25, 26] .
Starvation induces the breakdown of these TG into free fatty acids (FFA) and glycerol, which are released into the circulation ( Figure 2B ). FFA then serve as fuels for metabolically active tissues such as the skeletal muscle where their oxidation to carbon dioxide and water generates ATP. In the liver, most of the acetyl CoA produced by FFA oxidation is used to synthesize ketone bodies (acetoacetate; b-hydroxybutyrate), which are released into the circulation and used as fuels by the peripheral tissues. The glycerol generated by TG hydrolysis serves for the synthesis of glucose, which is reserved for cells depending on it as an energy source (neurons, red blood cells), or participates in the hepatic production of TG [27] . These TG are then packaged within very low-density lipoproteins (VLDL) and released into the circulation from where they can return to WAT. Regulation of the TG stocks is crucial for survival, In the post-prandial state, the ingested nutrients reach the circulation in the form of triglycerides (in chylomicrons as VLDL), glucose, and amino acids. In this state the main metabolic activities are the oxidation of glucose for the production of ATP in most cells, and the storage of excess fuel molecules in adipocytes as triglycerides, in hepatocytes as proteins, glycogen, and triglycerides, and in skeletal muscle fibers as proteins and glycogen. In fuel-excess conditions, amino acid oxidation increases in proportion to increments in protein intake, regardless of carbohydrate and fat substrate availability. (B) Fasting induces breakdown of the triglycerides from WAT into free fatty acids and glycerol, both released into the circulation. Free fatty acids can be directly oxidized by skeletal muscle fibers for the production of ATP. Hepatocytes use glycerol for gluconeogenesis, and free fatty acids for ketone body synthesis. Both glucose and ketone bodies are important fuel molecules for the peripheral organs. In fuel shortage conditions, the extent to which amino acid oxidation rises above the minimum required rate depends on the proportion of the energy needs, which is covered by FFA, glucose, and ketone body oxidation. Stored molecules (triglycerides, glycogen, proteins) are indicated in bold capitals. Adapted in part from [240] . Functions of WAT and their regulation by PPARg 490 npg since without WAT and its lipid reserve, animals would have to eat continuously, which is obviously not possible. For well-known reasons, food intake occurs only in distinct episodes underscoring the importance of a control of lipid production or intake, storage, and utilization.
Regulation of lipid metabolism in adipocytes is controlled at three levels: fatty acid uptake, lipogenesis, and lipolysis. Each of these processes is controlled by extracellular stimuli, including insulin, corticoids, catecholamines, natriuretic peptides, and cytokines such as TNF-α, whose levels depend on conditions such as age, gender, physical activity, and nutritional factors [28] . In addition, there are marked differences between the vis and sc adipose tissues in the regulation and levels of lipid metabolic activities. For instance, nearly 80% of fat is in the sc tissue, but the lipolytic effect of catecholamines is more pronounced in the vis fat whereas the antilipolytic effect of insulin is stronger in the sc fat [21] .
The adipose tissue participates in the regulation of glucose homeostasis, which depends on the action of other organs as well (pancreas, liver, brain). Firstly, it is involved in glucose disposal, which, via the glycolytic pathway, provides the substrate for the de novo synthesis of fatty acids and glycerol (and thus lipogenesis). Too little or too much adiposity is associated with hyperglycemia and insulin resistance. Not surprisingly, by liberating FFA into the circulation, the adipose tissue influences insulin sensitivity and thus glucose metabolism in the muscle and liver. Furthermore, among other functions, FFA serve as a substrate for lipoprotein assembly in the liver, regulate insulin production in the pancreas, and bind to and activate the transcription factors Peroxisome Proliferator-Activated Receptors (PPARs) in all tissues, which in turn results in gene expression changes and their consequences (see below) [10, [28] [29] [30] . Thus WAT, by being involved in the regulation of lipid and glucose metabolism, not only in adipocytes but also in the whole body, plays an important integrative role in energy homeostasis especially in extreme conditions when food is available on a very irregular basis and/or is of variable nutritional quality.
In mammals, when excess energy is not directed correctly into sc fat, it will preferentially accumulate in vis WAT, with deleterious effects, a condition often associated with a genetic susceptibility to vis fat obesity, and/or an endocrine-related maladaptive response to stress or smoking [31] . When the adipose tissue is deficient, for instance because it is insulin resistant, or is abnormally distributed (lipodystrophy), the extra TG will be deposited ectopically in muscle, liver and heart, and to some extent also in the pancreas, which will be detrimental to the normal functioning of these now abnormally lipid-loaded tissues. This will impact on whole-body metabolism with the development of features of metabolic syndrome as a consequence ( Figure  3 ) [31] .
WAT as an endocrine gland
For long regarded as a mere inert fat store for metabolic demands associated with fasting or exercise, WAT has finally emerged as a bona fide endocrine gland able to integrate hormonal signals from different parts of the body and respond by secreting its own signaling polypeptides called adipokines. These mediators have an impact on multiple target organs, such as the liver and skeletal muscle, and directly participate in the general control of the energy balance. Several of these adipokines, such as leptin and adiponectin, mediate some of their effect through activation of neuronal circuits in the hypothalamus and other brain areas with an impact on systemic regulation of energy Figure 3 Obesity and lipodystrophy alterations of the WAT induce activation of the innate immune system, which is responsible for a low-grade inflammation of the tissue as well as an increased expression of several deleterious adipokines. Therefore, the plasma levels of adipokines, FFA, TG, and glucose are increased. Ectopic fat accumulation in the liver, skeletal muscle, or the pancreatic beta cells will alter their functioning and in consequence will affect the whole-body energy balance and promote the development of the metabolic syndrome. [32] . Besides the production of these adipokines, WAT, under stress conditions, also secretes pro-or anti-inflammatory cytokines, with autocrine and/or paracrine effector functions contributing to the control of energy homeostasis. Both the production and secretion of adipokines and pro-or anti-inflammatory cytokines by the WAT are regulated by the overall WAT mass (obesity or lipodystrophy) and the physiological status of the organism [33] . Only a few major adipokines will be considered further, namely those that have been implicated in the direct modulation of metabolism as well as pro/anti-inflammatory cytokines, which are produced under stress conditions and indirectly affect energy homeostasis.
Adipokines directly involved in energy homeostasis
As mentioned previously, adipocytes have a high capacity to produce and secrete adipokines, which act in an autocrine, paracrine or endocrine fashion to control several functions, including lipid and glucose metabolism, and insulin secretion. Deregulation of these processes contributes to the development of the metabolic syndrome. Although several adipokines involved in energy homeostasis were discovered in recent years, the so far most studied ones are leptin, adiponectin, resistin, angiopoietin-like protein 4, and preadipocyte factor 1, on which this section will concentrate. In addition, information on other adipokines is given in Table 1 and Figure 4 , or can be found in several review articles [26, [34] [35] [36] [37] [38] .
Leptin (from the Greek leptos, meaning thin) is a small 16 kDa polypeptide of 167 amino acids produced mainly by adipocytes, in direct proportion to adipose tissue mass. Its production is increased by estrogens, glucocorticoids, insulin, TNF-α, and C/EBPα, and decreased by PPARg agonists, FFA, growth hormone, androgens, and β3-adrenergic activity. It is secreted in higher amounts by sc compared to vis fat ( Figure 1 ). It reduces food intake through a direct effect on the hypothalamus [39] . These observations contributed to viewing leptin as an antiobesity hormone, but it is now thought that it serves primarily as an energy sufficiency signal, whose levels decrease with weight loss or caloric restriction. Reduction in leptin levels during starvation is associated with adaptive responses including decreased energy expenditure and increased appetite. In several obesity models, the role of leptin is less obvious, since there was no improvement in spite of high endogenous leptin levels or treatment with exogenous leptin. Evidently, the target tissues have become resistant to leptin action, but the mechanism of this resistance remains unknown [40] . However, hyperleptinemia induced by overnutrition prevents ectopic lipid deposition by acting on appetite via the hypothalamus, thereby limiting energy surplus storage in the available adipocytes. Furthermore, ectopic lipid deposition is minimized by increasing fatty acid oxidation and decreasing lipogenesis in peripheral tissues [41] . In addition, the WAT itself has a leptin receptor-mediated energy regulating system, which is turned-off during overnutrition allowing the storage of excess calories and thereby diet-induced weight gain. This downregulation of the regulatory mechanism protects the whole organism against toxic ectopic lipid accumulation by permitting lipid accumulation in WAT [42] . The organism appears most leptin sensitive in a range between low levels of the adipokine in situations of food restriction and its increasing levels during re-feeding, rather than in its supraphysiological concentrations such as those occurring in obesity [43] . Exogenous leptin improves glucose homeostasis in ob/ob and lipodystrophic mice [44, 45] . It also improves glucose homeostasis in humans with congenital leptin deficiency or lipodystrophy, but has little effect on classic obesity [46] [47] [48] . In addition to its role in energy homeostasis, leptin has important endocrine functions, including the regulation of the hypothalamic-pituitary-adrenal and gonadal axes, bone development, immune response, angiogenesis, and hematopoiesis, which will not be reviewed here [49, 50] .
Adiponectin, also referred to as AdipoQ or adipocyte complement related protein 30 (Acrp30, GBP28, apM1) [51] is a mature adipocyte-specific secretory protein with a molecular weight of approximately 30 kDa, which shares homology with complement C1q, and types VIII and X collagen. Its expression is higher in sc than in vis fat ( Figure  1 ), and post-translational hydroxylation and glycosylation produce multiple isoforms. It circulates in serum at high concentrations (several micrograms per ml) as a hexamer of relatively low molecular weight and a larger multimeric structure of high molecular weight (12-18 subunits). Its biological effects depend both on the circulating concentrations and properties of the different isoforms, and on the tissue-specific expression of the two adiponectin receptors (AdipoR1 and AdipoR2) distantly related to the G protein-coupled receptor [51] . In some cells, T-cadherin may function as a co-receptor to transmit adiponectin metabolic signals [52] . Experimental data suggest that adiponectin has antidiabetic, anti-inflammatory and antiatherogenic effects [37, 53] . Only the former are summarized here, since they play important roles in energy homeostasis, obesity, and insulin sensitivity. In mice, decreased adiponectin is involved in the development of insulin resistance in models of both obesity and lipoatrophy [54] . Adiponectin stimulates phosphorylation and activation of the 5′-AMP-activated protein kinase in skeletal muscle and the liver, thereby regulating insulin sensitivity and glucose metabolism [55] . In muscle, adiponectin stimulates fatty acid oxidation and glucose catabolism, and in the liver it reduces glucose npg output and FFA influx, and increases fatty acid oxidation and insulin sensitivity. In Rhesus monkeys, plasma levels of adiponectin were shown to decrease parallel with reduced insulin sensitivity even before the onset of type 2 diabetes [56] , and in Japanese men with type 2 diabetes, hypoadiponectinemia was found to be associated with vis fat accumulation and insulin resistance [57] . In contrast, an increase in adiponectin levels is observed after administration of thiazolidinediones (TZDs), angiotensin-converting enzyme inhibitors, and the angiotensin II receptor blocker (ARB), after weight loss, renal failure, heart failure, or after intake of soy protein or oils [51] . Other effects of adiponectin on monocytes/macrophages, angiogenesis, and nitric oxide production are not discussed here.
Resistin (resistance to insulin, also called FIZZ3 or ADSF) is another small protein (12.5 kDa) and a member of the hormone family of cysteine-rich resistin-like molecules [58] , which is mainly produced and secreted by WAT and Abbreviations: IR, insulin resistance; TG, triglycerides; PBEF, pre-B-cell colony-enhancing factor; Vaspin, visceral adipose-tissue-derived serine protease inhibitor; LPL, lipoprotein lipase; FIAF, fasting-induced adipose factor; ANGPTL4, angiopoietin-like protein 4; RBP4, retinol-binding protein 4; sc, subcutaneous; om, omental; SVC, stromal vascular cells; Apelin, APJ endogenous ligand; Acrp30, adipocyte complement-related protein 30; FIZZ3, found in inflammatory zone; ADSF, adipose tissue-specific secretory factor. appears to increase glucose production in the liver by a specific insulin antagonizing action [59] . In rodents, it is expressed 15 times more in vis compared to sc fat ( Figure  1 ) and it is highly upregulated in models of diet-induced obesity, as well as in genetic models of obesity and diabetes. Resistin circulates in multimeric forms, probably corresponding to trimers and hexamers, the conversion of the latter to the trimeric form most likely representing an obligatory step towards activation [60] . Mice treated with recombinant resistin develop insulin resistance and glucose intolerance, while cultured adipocytes receiving the same treatment are impaired in insulin-stimulated glucose uptake, suggesting that resistin affects insulin action. Resistin-null mice have similar fat mass and weight as wild-type (WT) mice and show improved glucose homeostasis associated with a decrease in hepatic gluconeogenesis [59, 61, 62] . In addition, resistin appears to be a pro-inflammatory cytokine. There are substantial inter-species differences between the sites of resistin production, occurring, for example, in adipocytes in rodents, and most likely non-fat cells, macrophages or other stromal cells present in the adipose tissue in humans [63] [64] [65] [66] . The role of resistin in humans is not well established, since clinical studies do not show a clear link between obesity and insulin resistance versus resistin levels [67, 68] . Angiopoietin-like proteins (ANGPTLs) are also involved in the regulation of energy homeostasis [69] . One of them, the fasting-induced adipose factor (FIAF), also called ANGPTL4, HFARP and PGAR [70] [71] [72] [73] , is most highly expressed in the adipose tissue and secreted into the circulation, where it is found associated with plasma lipoproteins. Adenovirus-mediated overexpression of FIAF was found to improve hyperinsulinemia, hyperglycemia and glucose tolerance [74] . Yet it is a powerful signaling molecule that inhibits plasma TG clearance and thus fat storage, and promotes TG mobilization by stimulating adipose tissue lipolysis possibly by the inhibition of lipoprotein lipase activity [75] . Thus, FIAF is efficient in both reducing blood glucose and improving insulin sensitivity, while simultaneously promoting hyperlipidemia and fatty liver. Although much remains to be discovered about this intriguing dual function of FIAF, one can speculate that it connects adipose tissue to the modulation of the levels of plasma lipids. Modification of FIAF production and signaling may contribute to the development of dyslipidemia and possibly type 2 diabetes [75] .
Lastly, proteolytic cleavage of the transmembrane protein preadipocyte factor 1 (Pref-1), highly expressed in preadipocytes, but not in adipocytes where it plays the role of an inhibitor of adipogenesis, gives birth to two soluble proteins of 50 and 25 kDa. In transgenic mice, overexpression of Pref-1 specifically in WAT reduces the expression of adipocyte proteins such as leptin and adiponectin, and produces substantial loss of WAT, while these mice suffer from hypertriglycemia, impaired glucose tolerance and decreased insulin sensitivity. These findings demonstrate 
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npg that Pref-1-induced impairment of adipocyte functions in vivo leads to the development of metabolic abnormalities [76] .
Adipokines, chemokines, and vascular proteins involved in pro/anti-inflammatory reactions
Several molecules involved in inflammatory processes are produced by the adipose tissue in situations of stress, such as in obesity or lipodystrophy. Some of these adipokines are synthesized by adipocytes, whereas others are produced by the haematopoietic cell fraction of the WAT (in macrophages, T-cells, B-cells, natural killer cells), or cells from the SVF [36, 77, 78] . A large number of studies suggest that adipose tissue inflammation is associated with metabolic diseases, such as insulin resistance and other obesity-related complications, and lipodystrophy [79] [80] [81] [82] [83] [84] (reviewed in [85] ). Most of the better-defined adipokines, which are involved in inflammation, are discussed briefly in this section, while a more exhaustive list is given in Table 2 and Figure 4 .
The plasmatic levels of TNF-α, a 26-kDa transmembrane protein that is cleaved to a 17-kDa biologically active Abbreviations: IR, insulin resistance; TNF-α, tumor necrosis factor alpha; IL-1, interleukin 1; IL-6, interleukin 6; TGF-β, transforming growth factor beta; IL-1Ra, interleukin 1 receptor antagonist; IL-10, interleukin 10; MCP1, monocyte chemotactic protein 1; IL-8, interleukin 8; RANTES, regulated upon activation, normally T-expressed, and presumably secreted; IP10, interferon gamma inducible protein 10; PAI1, plasminogen activator inhibitor 1; TF, tissue factor. Figure 1) . However, the TNF-α produced by the adipocytes has only a local effect since it cannot be secreted. Thus, it is the macrophage-produced TNF-α that is responsible for the systemic effects [86] . Although there is no clear correlation between obesity and insulin resistance versus levels of plasma TNF-α, expression of this cytokine in WAT correlates with these two pathologies [87, 88] . Chronic exposure of mice to TNF-α induces insulin resistance, decreases the expression of genes involved in adipogenesis and lipogenesis in WAT, and promotes lipolysis, while deletion of the TNF-α gene improves circulating FFA and insulin sensitivity in mouse obesity [89] . Besides its role in WAT, TNF-α increases the expression of genes involved in the de novo synthesis of FA, and decreases that of genes involved in FA oxidation in liver. The autocrine and paracrine effects of TNF-α are responsible for the insulin resistance observed in humans and rats to whom this cytokine has been administrated [90] [91] [92] . TNF-α also regulates the expression of other adipokines in WAT. For instance, it downregulates the expression of adiponectin and increases the expression of IL-6, another cytokine involved in the endocrine role of WAT (see below) [93] . IL-6 is found at high levels in the plasma in multiple glycosylated forms ranging from 22 to 27 kDa, a third of which is produced by adipocytes. Its synthesis and secretion are approximately three times greater in vis compared to sc adipose tissue. The plasma levels of IL-6 positively correlate with fat mass, obesity, impaired glucose tolerance and insulin resistance, and thus could be used to predict the development of type 2 diabetes and cardiovascular diseases [6, 94] . IL-6, like TNF-α, modulates the insulin sensitivity of the liver and of skeletal muscle, thereby supporting the notion that cytokines produced by the adipose tissue influence whole-body insulin sensitivity. It is thought that IL-6 increases the expression of Socs-3 (inducing-suppressor of cytokine signaling-3) that negatively regulates insulin and leptin signaling. Central administration of this cytokine in rodents decreases body fat by increasing energy expenditure. In line with this effect, transgenic mice overexpressing IL-6 have reduced fat pad and body weights, which are associated with a growth defect [95] [96] [97] .
In humans, the circulating levels of TGF-β 1 , a homodimer composed of two 12.5-kDa subunits, correlate positively with the body mass index (BMI) [98] . This correlation also exists between the BMI and TGF-β 1 production in WAT, a feature that holds especially for the vis WAT that produces more than two-fold more TGF-β 1 compared to the sc WAT in humans [99, 100] . However, the adipocytes are not the main producers of WAT TGF-β 1 , as the non-fat cells in the adipose tissue release more than 90% of it, production of which can be inhibited by TNF-α as well as by IL-1 [99] . In addition to its association with adipogenesis, TGF-β 1 has multiple functions in a wide range of tissues, which will not be discussed here.
Mature monocytes produce monocyte chemotactic protein 1 (MCP1), a non-glycosylated 76 amino-acid polypeptide (8.7 kDa) usually found at low levels. IL-1, TNF-α and LPS rapidly induce its expression and secretion. MCP1 expression in WAT and MCP1 circulating levels are increased in obesity (rodents and humans). Conversely, its circulating levels are reduced parallel to weight loss [101] . In vis WAT especially, MCP1 is not only produced by the infiltrated macrophages but also by adipocytes [102] . In adipocytes, MCP1 influences lipid metabolism by downregulating PPARg, which regulates lipid accumulation in these cells (the roles of PPARg will be further discussed later). Moreover, MCP1 also stimulates leptin secretion and decreases insulin-stimulated glucose uptake in adipocytes. Transgenic animals overexpressing MCP1 in WAT only develop a normal adipose depot mass, but the tissue is infiltrated by an increased number of macrophages and produces elevated amounts of TNF-α and IL-6. Furthermore, the plasmatic levels of FFA in these animals are increased, most likely reflecting an increased lipolysis. In addition, the overexpression of MCP1 in WAT influences insulin sensitivity in the liver and especially in skeletal muscle, where it disturbs the insulin signaling pathway [51, 86, 103] . Consistently, these mice become insulin resistant and glucose intolerant. These observations indicate that deregulation of cytokine expression in WAT can affect the overall metabolism of the body, particularly its insulin sensitivity [103, 104] . Furthermore, it suggests that MCP1-mediated macrophage infiltration of fat might contribute to metabolic deregulations associated with insulin resistance and obesity. In rodent obesity, increased circulating levels of MCP1 positively correlate with increased monocytes, a phenotype also seen after peripheral administration of MCP1 to mice. In these animals, accumulation of monocytes in collateral arteries and enhanced neointimal formation might implicate MCP1 in the development of atherosclerosis.
At least two proteins, plasminogen activator inhibitor-1 (PAI1, 45 kDa) and tissue factor (TF, 47 kDa), which are involved in the fibrinolytic system and vascular hemostasis, are secreted by the WAT. PAI1 is a serine protease inhibitor protein (serpin) that is the principal inhibitor of tissue plasminogen activator and urokinase, which activate plasminogen and hence cause the physiological breakdown of blood clots (fribrinolysis). This protein is expressed and secreted in the WAT of rodents (higher in vis compared to sc adipose tissue) and humans, where its expression is regulated by TNF-α and TGF-β 1 , themselves produced by npg WAT [100, 105] . The circulating levels of PAI1 are correlated with obesity and insulin resistance, and thus predict future risk of type 2 diabetes and cardiovascular disease [106, 107] . The adipose tissue is thought to be an important contributor to the elevated plasmatic PAI1 concentrations in obesity [108, 109] , but the mechanisms underlying the association between PAI1 levels and the disturbances found in the metabolic syndrome are not well understood. However, inhibition of fibrinolysis by PAI1 might be responsible for the high incidence of cardiovascular diseases, which is a feature of this syndrome [110] .
TF is a protein released from damaged tissue that triggers the clotting cascade. It acts as a cell-surface receptor for the activation of factor VII. Its expression is upregulated in the WAT of ob/ob mice [111] . Besides its role in coagulation, TF is thought to be involved in vascular development and integrity [112] . In obesity, where the adipose mass is greatly increased, the need for oxygen supply is dramatically augmented. In this condition, it is likely that TF is involved in the angiogenesis associated with fat mass expansion.
Several proteins of the classic renin angiotensin system (RAS) are synthesized in the WAT. Adipose tissue RAS is considered to be a potential link between hypertension and obesity. The intimate relationship between WAT and RAS may also have a role in the pathophysiology of type 2 diabetes, especially in obese individuals. These points have been addressed in different review articles [43, 113, 114] . Finally, the adipose tissue also expresses a variety of enzymes implicated in the activation, inter-conversion, and inactivation of steroid hormones that are also involved in the regulation of metabolic pathways. This role will not be discussed here as it has been reviewed recently [115] . Similarly, the role of adipokine in the interaction between adipose tissue and immunity has been summarized recently and will not be presented here [34, 77] .
Pathologies of the WAT
From the above, it has already become obvious that balanced amounts of adipose tissue are critical for an optimal regulation of lipid and glucose metabolism. Excess adiposity contributes to the development of insulin resistance, dyslipidemia, inflammation, hypertension, and cardiovascular diseases, while selective loss of WAT, called lipodystrophy, also predisposes to the same complications ( Figure 3 ). Both branches of these deregulations, obesity and lipodystrophy, are addressed below.
Obesity
When the energy balance is positive, as often occurs with western diet, the adipose tissue becomes hypertrophic and subsequently hyperplastic. Since the adipocytes cannot expand beyond a "critical size", which is thought to be genetically established for each depot type, the adipocyte number is increased when this critical point is reached [116, 117] . Combined together, cell size and cell number increases lead to an expansion of the adipose tissue, which ultimately results in obesity [7] .
Obesity produces what is called a "low-grade" inflammatory reaction in the adipose tissue by a mechanism that remains largely unknown [118] . As presented in a former section, autocrine, paracrine, and endocrine signals from adipocytes, together with increased adipose tissue mass stimulate the synthesis and secretion of adipokines that trigger macrophage infiltration in the WAT. As already mentioned, there is a positive correlation between the adipocyte size and BMI, and the increase in adipokine expression in WAT [101, [119] [120] [121] [122] . This low-grade inflammation is thought to result from a chronic activation of the innate immune system [83] . The involvement of obesity in this process was suggested by the decrease of inflammation in the WAT of obese patients after weight loss [101, 123] . Low-grade inflammation in WAT impairs its ability to control plasmatic FFA, promotes its deleterious endocrine function, and ultimately leads to insulin resistance, impaired glucose tolerance, and may result in diabetes and cardiovascular diseases (Figure 3) .
It was shown in models of obese rodents as well as in humans that obesity is linked to an increase in adipocyte size. This hyperplasia is associated with an increased number of necrotic-like dead adipocytes surrounded by infiltrated macrophages, and the progressive up-regulation of inflammatory genes, such as TNF-α within the WAT. Moreover, this up-regulation precedes the dramatic increase in the circulating insulin levels, suggesting that the inflammatory reaction in the WAT is responsible for systemic insulin resistance. In addition, the persistence of WAT inflammation is responsible for the maintenance of insulin resistance in obese models [84, 86, 121, [124] [125] [126] .
The genetics of human obesity unveiled the key role of leptin and melanocortin pathways, but only in rare cases. In fact, it is more a myriad of polymorphisms in genes and candidate regions, which defines the susceptibility of an individual to weight gain, a susceptibility that is accentuated by a permissive environment (diet, sedentarity) [127] .
Lipodystrophy
Lipodystrophies are characterized by the absence of fat store development, the altered distribution of these reserves or their loss with, as a consequence, an excess accumulation of lipids in the liver, skeletal muscle and other organs, along with the emergence of insulin resistance (Figure 3 ) [128] . It was demonstrated recently in mice that the membrane-anchored metalloproteinase MT1-MMP is required for WAT development and function. In its absence, the animals are npg lipodystrophic. MT1-MMP governs the interaction between the adipocyte and the extracellular matrix, and hence acts as a three-dimensional-specific adipogenic factor [129] .
The different human lipodystrophic syndromes are defined by an altered quantity and/or distribution of adipose tissue (lipoatrophic peripheral sc fat and increased vis fat). In humans, the classification of lipodystrophies is usually made according to their origin, either genetic or acquired. Among the inherited lipodistrophies, some are better characterized, among which are the familial partial lipodystrophy Dunnigan-type (FPLD) and the familial generalized lipoatrophy known as Berardinelli-Seip congenital lipodystrophy (BSCL). FPLD is characterized by a loss of sc fat, while the inter-and intra-muscular fats as well as the abdominal fat are preserved. In adult patients, insulin resistance and type 2 diabetes correlate with an increase in plasma TG and FFA concentrations as well as the presence of C-reactive protein. Several FPLD patients also suffer from dyslipidemia and hypertension. In 50% of the FPLD families, there is a link between FPLD and the LMNA (lamin A) gene also associated with premature forms of aging, which codes for the nuclear envelope protein lamin A/C [130] . Different mutations in this gene have been identified as culprits for lipodystrophy, but the mechanism by which it occurs is not known [131] [132] [133] . Mutations in the LMNA gene are linked to a decrease in the plasma concentrations of adiponectin and leptin, and an increase in circulating TNF-α concentrations, which may cause the insulin resistance observed in FPLD patients [134] . Another gene involved in FPLD encodes PPARg, a transcription factor involved in adipogenesis.
BSCL is a generalized lipoatrophy characterized by the total loss of WAT, which is associated with insulin resistance and increased plasma TG levels. It is caused by mutations in two genes independently linked to this pathology. These genes encode seipin, a protein of unknown function, and 1-acylglycerol-3-phosphate-acyl transferase, which is involved in TG synthesis [135, 136] .
Among the acquired lipodystrophies, the most common is the one associated with the antiretroviral treatments in HIV-infected patients. Fifty percent of these patients suffer from lipoatrophy, often associated with dyslipidemia, impaired glucose tolerance and diabetes. Interestingly, treatment of the patients with protease inhibitors (which are a part of the pharmacopoeia of HIV treatment) markedly alters the expression and secretion of adipokines from WAT. While adiponectin expression and secretion are decreased, IL-6 and TNF-α expression is upregulated in these patients. In WAT, increase in the production of these inflammatory cytokines is correlated to a decrease in adipocyte size, an increase in fibrosis, and infiltration of macrophages [137] [138] [139] [140] .
Altered metabolism due to the loss of WAT is also observed in mouse models of lipodystrophy. Induced fat-cell apoptosis through targeted activation of caspase 8 causes WAT distrophy, glucose intolerance, and signs of inflammation [81] . The same phenotype of adipocyte death, WAT fibrosis, macrophage infiltration, and increased inflammation is seen in mice with PPARg specifically deleted from WAT in adult animals (see below) [141] .
In conclusion, the study of lipodystrophy resulting from an impaired development of body fat or, alternatively, its altered distribution revealed a link between this pathology and deregulation of lipid and glucose metabolism with insulin resistance. Therefore, lipodystrophic patients, independent of the origin of lipodystrophy, either genetic or acquired, suffer from major complications with a prevalence of diabetes, cardiovascular diseases, pancreatitis, and liver steatosis with an evolution towards cirrhosis. Treatments with hypoglycemic and hypolipidemic drugs are beneficial therapeutic options for these patients, and for those with very low leptin levels, leptin treatment provides a major improvement [142, 143] .
Role of the PPARg in WAT
Adipocyte differentiation is intimately associated with the pathologies linked to WAT such as obesity, lipodystrophy, and inflammation, as described above. PPARs compose a subgroup of three receptors, belonging to the nuclear hormone receptor family, and acting as lipid sensors to modulate gene expression [144, 145] . They are implicated in both major metabolic regulations and processes controlling cellular fate [146] . In this part of the review, we will concentrate on one of the three PPAR isotypes, PPARg, which is a pivotal coordinator of adipocyte differentiation and fatty acid uptake and storage ( Figure 5 ).
PPARg and adipocyte differentiation at the cellular level
Both adipocyte number and adipocyte size are major contributors to adipose tissue mass. Therefore, adipocyte differentiation is crucial in the maintenance of adipose tissue integrity. Adipocytes are either derived from resident differentiated preadipocytes or from progenitor cells [147, 148] . PPARg is a key player in this process ( Figure 5 ). It has been recently shown that activated PPARg not only stimulates differentiation to adipocytes of resident adipose tissue preadipocytes but also promotes the mobilization of bone marrow-derived circulating progenitor cells to WAT and their subsequent differentiation into adipocytes [149, 150] . These results add an unexpected dimension to the field since they demonstrate, for the first time, that cells that reside outside the adipose tissue can influence and contribute to its fate. npg Alternative promoter usage gives rise to two PPARg isoforms. PPARg 1 is the ubiquitous isoform found in all PPARg-expressing tissues such as WAT, BAT, macrophages, liver, skeletal muscle, kidney, colon, vascular endothelium and others [151, 152] . PPARg 2 has a 30 (rodents) or 28 (human) residue N-terminal extension over that of PPARg 1 , and is expressed primarily in adipose tissue [153, 154] . The role of PPARg 1 and PPARg 2 as key regulators of adipocyte differentiation from preadipocytes was shown by several groups [154] [155] [156] . Based on cellular studies, the differentiation of preadipocytes to adipocytes can be divided into four steps. First, the preadipocytes are withdrawn from the cell cycle, and genes responsible for the "preadipocyte phenotype" are downregulated. The second step, called the "mitotic clonal expansion", allows a last round of cell division. Next, 48 h after the initiation of differentiation, the cells start to acquire the "early adipocyte phenotype", which represents the third step. Fourth, in the "differentiated adipocytes", genes already expressed at low levels in the early adipocyte phenotype, are now at their maximal expression levels, especially genes involved in energy storage and fat metabolism, such as C/EBPβ and PPARg [157, 158] . 3T3L1 cells, frequently used as adipocyte differentiation models, which have been manipulated to express small interference RNA (siRNA) against PPARg or embryonic stem cells (ES cells) deficient for PPARg (PPARg-/-), are unable to differentiate into adipocytes. These defects in PPARg expression reveal the important involvement of the receptor in this differentiation process, especially in the transition between the "mitotic clonal expansion" and the acquisition of the "early adipocyte phenotype" [159, 160] . Conversely, experiments on gain of function, using retroviral expression of PPARg in cultured fibroblasts, as well as treatment of fibroblasts with PPARg agonists, were shown to stimulate adipogenesis [161] .
Obviously, PPARg is not the only transcription factor controlling the differentiation of mesenchymal cells to adipocytes, but a major player in a sophisticated network of transcription factors and their co-repressors and coactivators, which respond to specific stimuli to repress or stimulate adipocyte formation. The elegant cascade of transcription factor signaling in the regulation of adiposeness has been reviewed recently [162] , and therefore will not be discussed further here.
PPARg and lipid storage
In addition to being involved in the differentiation of adipocytes, PPARg participates in the function of the mature cells. Indeed, PPARg is the major regulator of lipid storage in WAT [163] . It promotes the release of FFA from circulating lipoproteins by regulating lipoprotein lipase expression [164] , and stimulates their uptake by enhancing npg the expression of the fatty acid translocase CD36, and of the fatty acid transport protein FATP1 [165] [166] [167] . Furthermore, PPARg regulates the intracellular retention/transport of FFA by controlling the expression of fatty acid binding proteins [168] . It also promotes the esterification of FFA into TG and their storage by regulating the expression of enzymes such as phosphoenol pyruvate carboxykinase, glycerol phosphate dehydrogenase, and diacylglycerol O acyltransferase. Expression of perilipin, which is the predominant protein associated with adipocyte lipid droplets and has a key function in regulating adipocyte lipid storage and body fat accumulation, is stimulated, too [167, [169] [170] [171] [172] [173] [174] . Finally, PPARg participates in the de novo FFA synthesis by regulating directly or indirectly the expression of enzymes such as fatty acid synthase, acetyl CoA synthetase, and stearoyl CoA desaturase 1 ( Figure 5 ) [163, 166, 167, 175] .
Ablation of PPARg expression and activity in WAT: lessons from mouse models and human genetics
Studies on the role of PPARg in WAT have been stimulated by the finding that TZDs, now used to treat patients suffering from type 2 diabetes, are specific ligands of PPARg. Most of the present knowledge on PPARg functions in energy homeostasis and its deregulations derives from the use of animal models and the investigation of patients bearing variant forms of the PPARg gene ( Figure 5 ).
Mouse models
General ablation of the PPARg gene in mice is lethal due to placental malformation [176] . In a model of generalized PPARg ablation where embryonic lethality is prevented by preserving PPARg expression in trophoblasts, severe lipodystrophy, insulin resistance and hypotension, probably due to increased vascular relaxation, were observed [177] . On the contrary, the PPARg+/-heterozygous animals are viable and do not present any major defects except mild growth retardation in males, possibly due to a deregulation of growth hormone signaling in the WAT [178] . The PPARg+/-mice have normal insulin sensitivity under a standard diet. However, when on a high-fat diet (HFD) and compared to WT animals, they are protected against fat mass increase, which is reflected in smaller adipocytes. Furthermore, they do not develop insulin resistance or liver steatosis, and display a substantial increase in FA oxidation in the liver and in skeletal muscle [179] [180] [181] .
Specific deletion of PPARg in WAT has led to a better understanding of pathologies linked directly to PPARg dysfunction in this tissue. Three different laboratories performed this specific genetic manipulation. In a first study, using mutant animals on a standard diet, adipocyte hypocellularity and hypertrophy were observed, involving an increase in the levels of plasma TG and FFA, and a decrease in leptin and adiponectin levels, which were accompanied by increased hepatic gluconeogenesis and insulin resistance. This latter was reversed by TZD treatment that, however, failed to lower circulating FFA. These animals were more susceptible to HFD-induced steatosis, hyperinsulinemia and associated insulin resistance [182] . A similar phenotype was observed in a "knock in" mouse model using the dominant-negative mutant PPARgL466A, which again showed the relationship between PPARg function, adipose tissue and typical metabolic syndrome pathologies. Homozygous PPARgL466A mice died in utero, similar to PPARg-/-mice [183] .
In a second ablation study, mutant mice lacking PPARg in adipose tissue were fed HFD, following which they presented diminished weight gain and plasma levels of adiponectin and leptin, but, in contrast to the first study, did not develop systemic insulin resistance or glucose intolerance. Furthermore, the mice exhibited diminished glucose uptake in the skeletal muscle, which suggests insulin resistance in this tissue. However, the liver did compensate for this insulin resistance by increasing glucose uptake and utilization, thereby improving the overall systemic insulin sensitivity. This improvement coincided with an increased expression of PPARg in the liver, where it might have had a protective effect under these conditions [184] . The reason for the difference in insulin resistance between the two studies remains unclear, but different feeding protocols might be the cause. These studies also showed that several genes involved in lipid uptake and lipogenesis were downregulated. The resulting diminution of fat accumulation in the WAT of these animals most likely contributed to the plasmatic increase in FFA and TG concentrations as well as to hepatic steatosis. [182, 184] .
In the third study, ablation of PPARg was induced selectively in adipocytes after the animals had reached adulthood. PPARg-null adipocytes died within a few days after ablation of the gene, thus demonstrating that, in addition to its role in adipose differentiation, PPARg is essential for the survival of mature adipocytes [141] . In the studies discussed above, both isoforms PPARg1 and PPARg2 were deleted. When PPARg2 alone is selectively disrupted, the mutant mice develop normally and are viable. However, they display a reduced WAT mass with smaller and heterogeneous-in-size adipocytes reflecting less lipid accumulation, well in line with a decreased expression of lipogenic genes. However, there was no liver steatosis, and insulin resistance was observed in male mice only. It was corrected by TZD treatment, probably by the effect of this drug on the remaining PPARg 1 in WAT, liver, and skeletal muscle. This model underscores again that the integrity of the adipose tissue is primordial for a good whole-body energy balance as well as for systemic insulin sensitivity.
npg In addition, it shows that PPARg 1 alone can sustain development in general and drive adipose tissue formation in particular [185] .
Another model in which the expression of PPARg 2 and g 1 is blunted in WAT, without affecting PPARg 1 expression in the liver and skeletal muscle, but in which PPARg1 was found to increase in BAT, was called the PPARg hypomorphic mouse (PPARg hyp/hyp ) [186] . PPAR hyp/hyp mice present a severe lipodystrophic syndrome and a relatively high neonatal mortality. Even if the surviving mice develop hyperlipidemia, they present only limited metabolic consequences of the severe WAT lipodistrophy most likely because of compensation, particularly by muscles [186] .
The site of action of TZDs has been long debated and although not fully clarified yet, significant knowledge has come from the use of the A-ZIP/F1 fatless mouse that lacks WAT. These mice present a phenotype similar to that of humans with lipoatrophic diabetes, fatty liver, hyperlipidemia, and hyperglycemia and insulin resistance. Treatment of these animals with rosiglitazone and troglitazone (two PPARg agonists; see "PPARg as a therapeutic target in fatrelated diseases") showed that adipose tissue is required for the antidiabetic, but not for the hypolipidemic effect of TZDs [187] . Using the same model, it was shown that rosiglitazone enhances insulin action in skeletal muscle by the distribution of fat away from this organ, contributing at least in part to liver steatosis. Ablation of liver PPARg in the A-ZIP/F1 mice, while reducing steatosis, aggravates TG clearance problem, hyperlipidemia and, as a consequence, muscle insulin resistance [188, 189] .
The results obtained from these different mouse models underscore the link between adipogenesis and the metabolic syndrome [190] , and highlight the crucial role of PPARg for the development, integrity and well-functioning of the WAT. Adipocytes communicate with preadipocytes, monocytes/macrophages and endothelial cells within the adipose tissue and with the liver, skeletal muscle, pancreas and brain at the systemic level. Most importantly, it shows that deregulation of the WAT function and integrity, which often interferes with the production of secreted adipokines and other signaling proteins by the different cell types comprised in the WAT, ultimately affects the homeostasis of the whole body. A disturbance of this balance contributes to the development of the metabolic syndrome and associated risks [31] .
Human genetic studies
As highlighted by the animal models, PPARg is a determining factor for fat-related pathologies. Similarly, arrays of polymorphisms and mutations have been identified in the human PPARg gene, which are linked to metabolic phenotypes. Only mutations particularly informative on the role of PPARg in WAT will be discussed below, with regard to adipose mass (obesity and lipodystrophy), energy balance, insulin resistance, and low-grade inflammation.
PPARg loss of function mutations
Familial partial lipodystrophy (FPL) is associated with mutations in the PPARg gene in a few patients. This partial lipodystrophy affects limbs and buttocks, but spares abdominal sc fat that might be increased, causing insulin resistance, diabetes, high plasma TG levels, hypertension, and in some cases liver steatosis and polycystic ovarian syndrome.
A study of the PPARg gene in seven FPL patients revealed a heterozygous change of the highly conserved arginine 425 to cysteine, in exon 6, in one of the patients, a non-Hispanic white woman who developed type 2 diabetes and hypertriglyceridemia, and later lipodystrophy, of the extremities and face, while sc truncal fat was slightly increased [143] . Since arginine 425 might be involved in a salt bridge that maintains the PPARg protein in a proper configuration, it was speculated that this PPARgR425C mutation represents the molecular basis of one of the FPL phenotypes.
Another mutation, PPARgP467L, was found in two adult patients (man and woman) as well as a PPARgV290M mutation in a female patient. These adults also suffered from lipodystrophy at the extremities, elevated plasma TG concentrations, hyperinsulinemia, and fat accumulation in the liver. However, there was no difference in the circulating levels of leptin and TNF-α but a decrease in adiponectin levels in the two PPARgP467L patients [191] . In vitro studies of both mutations suggest a destabilization of the PPARg configuration more favorable for receptor-corepressor interactions with dominant-negative properties. Interestingly, a PPARg ligand stabilizes the receptor structure in the active conformation and promotes co-repressor release, which most likely explains the improvement of these patients' condition after TZD treatment [192] .
In addition, four members of a same family were identified, who suffered from a transactivation deficient mutant PPARg, namely PPARgF388L, which changes a highly conserved residue of helix 8 of the ligand-binding pocket [193] . All four patients were heterozygous carriers and presented partial lipodystrophy as well as hyperinsulinemia. Moreover, the older patients suffered from type 2 diabetes and hypertension. In transactivation assays, the basal transcriptional activity of the mutant receptor was three-fold lower compared to the WT molecule in the absence of an exogenous ligand. However, in the presence of TZD, its activity increased, comparable to the WT receptor only at high rosiglitazone concentrations. It is noteworthy that the proband, when treated with pharmacological doses of www.cell-research.com | Cell Research Silvia I Anghel and Walter Wahli 501 npg rosiglitazone, in combination with metformin, had a good glycemic control [193] . Another well-studied variant is the PPARg 2 P12A [70, 73, 194, 195] . This is the only well-described change found so far in the N-terminal domain of PPARg 2 . The initial study of Finnish and second-generation Japanese populations concluded that the less common 12A allele promotes insulin sensitivity and confers protection against type 2 diabetes [70, 73, 194, 195] . In vitro studies showed that this allele reduces PPARg DNA binding affinity and transcriptional activity [70, 73, 194, 195] . Although some additional studies did not support a statistically significant role for the PPARg 2 P12A polymorphism in the etiology of type 2 diabetes [196] [197] [198] , a more recent meta-analysis of all published data, comprising more than 25 000 cases of diabetes, showed an association of P12A with type 2 diabetes [199] . The large population that was necessary in order to demonstrate the association between P12A and type 2 diabetes is due to the weak effect of the risk allele, since individuals that are homozygous for the higher risk P12 allele have only a 25% increase in diabetes risk. However, because the frequency of the P12 allele is high in Europeans, it has a substantial effect at the level of this population, since the disease would be reduced significantly if the risk factor were not present [199] . Data from a recent study support the idea that additional PPARg variants, besides the one just described, most likely contribute to PPARg effects on metabolic traits in African-Americans and whites [200] .
In brief, the mutations found in the human PPARg receptor show that, in general, as in mice, the level of PPARg activity correlates with adiposity. Loss of PPARg function is linked to partial lipodystrophy, which in turn is associated with severe metabolic dysfunctions. This connection highlights once more the role of PPARg in the control of both lipid and glucose metabolism. Interestingly, a mild reduction in PPAR activity, as seen above with the 12A in humans, or with a partial antagonist in mice, promotes insulin sensitivity. In mice it also decreases fat depots, and brings the metabolic parameters to the levels seen in PPARg heterozygous mice [73, 178, 180] . These heterozygous mice are partially protected from high-fat diet or mono sodium glutamate-induced weight gain and insulin resistance. It is not known whether treatment of human diabetic patients with a partial PPARg antagonist would inhibit TG accumulation in fat tissue without redistribution to muscle and liver, thus promoting insulin sensitivity [201] .
PPARg gain of function mutations
The PPARgP115Q mutation, which was found in four unrelated patients, is the only one in humans that was found to increase PPARg activity. 115Q prevents the adjacent S114 from being phosphorylated (phosphorylation of this residue inactivates the receptor). All four patients were severely obese, lending additional support to the notion that increased PPARg activity promotes increase in fat mass. It is noteworthy that in a nation-wide German epidemiological field survey, no individual homozygote or heterozygote for the 115Q allele was found, showing that this mutation is unlikely to have a significant epidemiological impact on morbid obesity [202] . However, it certainly contributes to a better understanding of the role of PPARg activity on fat mass in humans.
Taken together, data from the mouse models and human genetic studies underscore a direct and positive correlation between PPARg and adiposity. Such a correlation appears less obvious between PPARg activity and insulin sensitivity. It may suggest that insulin sensitivity is achieved mainly by a modulation of PPARg activity within the WAT, possibly through its transcriptional effects on adipokine expression and secretion, as well as on lipogenic gene expression. Maintaining the integrity of the adipose tissue may fulfill this function. In fact, obese and lipodystrophic animals and humans both develop insulin resistance and associated pathologies.
PPARg as a therapeutic target in fat related diseases
To become transcriptionally active, PPARg depends on an indispensable partner, the Retinoid X Receptor, which is also a member of the nuclear hormone receptor family, with which it forms a heterodimer. This heterodimer binds to specific sequence elements in the regulatory regions of target genes, called Peroxisome Proliferator Response Elements (PPRE) and, in the presence of ligands, activates transcription. Fatty acids and prostaglandin J derivatives are natural ligands of PPARg [4, 10] .
Before even being identified formally as PPARg ligands, TZDs were shown to stimulate adipogenesis and to improve insulin sensitivity [203, 204] . It is only more recently that TZDs were described as selective ligands for the receptor, bridging the gap between PPARg and insulin sensitivity ( Figure 5 ) [205, 206] .
Supraphysiological activation of PPARg by TZDs stimulates adipogenesis by increasing the number of newly differentiated adipocytes, especially in the sc WAT. Increasing the storage capacity of WAT decreases ectopic lipid accumulation. The result is a decrease in liver and skeletal muscle TG content and an amelioration of insulin sensitivity at the expense of increased sc WAT mass. However, TZD amelioration of insulin sensitivity in skeletal muscle appears to be independent of the lipid profile of this organ, since the TZD treatment was shown to increase lipid ac-npg cumulation in skeletal muscle [207] . Lessons learned from the PPARg+/-mouse model, as mentioned above, as well as from clinical observations of obese patients after weight loss, which correlated with reduced PPARg levels, suggest that a moderate decrease in PPARg activity might have beneficial effects on the TG content of WAT, liver and skeletal muscle. In fact, diminution of PPARg transcriptional activity reduces the expression of the lipogenic program and promotes the β-oxidation pathway in the liver and muscle, with an improvement of plasma lipidic parameters as well as insulin sensitivity [179, 208, 209] .
Use of synthetic PPARg agonists in the treatment of lipodystrophies and type 2 diabetes
The effects of the TZD rosiglitazone were investigated in acquired or genetic lipodystrophies, including those caused by mutations in the PPARg gene (see above). In patients with inherited or HIV-induced lipodystrophies, treatment with rosiglitazone increases the sc fat mass, and augments insulin sensitivity and adipokine secretion, probably by increasing the lipogenic program in WAT [175, 210, 211] .
With respect to type 2 diabetes, several drugs have been introduced during the past decade, which are effective in lowering blood glucose and in reducing diabetes-related end-organ diseases. The two TZDs, rosiglitazone and pioglitazone, currently approved as antidiabetic drugs, are selective PPARg agonists. Troglitazone, the first agent of this class, effective in controlling glycaemia, was removed from the market because of serious liver toxicity.
In addition to improving insulin signaling, rosiglitazone and pioglitazone improve cardiovascular parameters, such as lipids (increase in sc WAT, influx of FFA), blood pressure, inflammatory biomarkers (inhibition of adipokine expression and action), endothelial function, and fibrinolytic status [212] [213] [214] . Furthermore, pioglitazone treatment shifts fat from the vis to the sc compartment in obese patients, a fat redistribution thought to improve insulin sensitivity since sc WAT confers less insulin resistance than vis WAT [208] . These observations are consistent with recent data from a report on the treatment of male rats with a PPARg agonist. Redistribution of fat by stimulation of the potential for lipid uptake and esterification in sc WAT was obtained, but only a minimal effect on uptake was achieved in vis WAT. More significantly, energy expenditure was strongly increased in vis fat with a consequent reduction in fat accumulation [215] .
Despite the efficacy and beneficial effects of TZDs, a number of undesired side effects have been noted, including increased weight gain due to both increased adiposity and fluid retention (edema) [216, 217] . The latter, which can be explained by PPARg stimulation of ENaC-mediated renal salt absorption [218] , might be the cause of an increased incidence of congestive heart failure [219] , an outcome also observed in rats where rosiglitazone treatment is associated with increased post-myocardial infarction mortality [220] . However, this issue is still under debate as the Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive) showed recently that treatment of type 2 diabetic patients with pioglitazone, another TZD drug, improved their cardiovascular outcome [113] .
At the present time, substantial effort has been concentrated on generating novel selective PPARg modulators that retain the beneficial clinical effects while avoiding the unwanted side effects.
Are PPARg antagonists candidate drugs for type 2 diabetes?
As mentioned above, PPARg activation reduces insulin resistance, but also increases fat mass by promoting adipocyte hypertrophy and hyperplasia. Since lasting enhanced adiposity is associated with increased insulin resistance, it was hypothesized that reducing PPARg activity would result in less fat mass and improved insulin sensitivity. In fact, mice treated with PPARg partial antagonists such as SR202, GW9662, or BADGE (bisphenol A diacylycidyl ether) showed decreased TG content in WAT, liver and skeletal muscle, decreased adipocyte size, increased resistance to HFD-induced obesity, and decreased expression and secretion of leptin and TNF-α. However, insulin sensitivity under HFD conditions depends on the type of antagonist that was administrated to the animals. SR202-and BADGEtreated mice presented an increased sensitivity to insulin, whereas GW9662 had no effect on insulin sensitivity [221] . Especially for SR202, the effect is comparable to the improved sensitivity recorded in untreated PPARg+/-mice, in which PPARg levels were reduced by half compared with WT animals. [221] [222] [223] [224] .
Several lines of evidence discussed above suggest that WAT dysfunctions resulting from lipodystrophies or experimentally induced loss of adiposity in animal models can also be linked to insulin resistance, possibly due to excessive levels of circulating FFA that could be lipotoxic for the liver, skeletal muscle and even for the pancreas (by affecting beta cell action). In addition, experimental disruption of the WAT in mice induces a low-grade inflammation, as in obese patients. Associated with adipokine and pro-inflammatory cytokine expression and secretion from the dysfunctional WAT, this inflammatory condition may affect insulin sensitivity. In line with this possibility, treatment of PPARg+/-mice (where the activity of the receptor is decreased by half) with the PPARg antagonist BADGE causes re-emergence of the lipotoxic effect of TG in liver and skeletal muscle, and insulin resistance [223] .
It would appear, therefore, that the use of PPARg an-503 npg tagonists over long periods of time might interfere with the integrity of the adipose tissue and trigger unexpected and undesired effects on whole-body metabolism, including insulin sensitivity.
Selective PPARg modulators: a better alternative?
To overcome side effects associated with the use of TZDs, a novel approach consists in developing new PPARg ligands that have insulin-sensitizing properties, via selective action on beneficial pathways, without exacerbating fluid retention and obesity. Such compounds are called "selective PPARg-modulators" (SPPARgMs) analogous to selective estrogen receptor modulators (SERMs) such as raloxifen, which spares the uterus functions, but acts as a partial ER agonist in bones [225] . SPPARgMs would separate the effects of PPARg on lipid and glucose metabolisms as well as on different organ systems (gastrointestinal, immune, cardiovascular). The selective action of such compounds is thought to depend on different structural configurations induced in the ligand-binding domain by their interaction with the receptor, allowing recruitment of different complexes of cofactors that impact on the activation or repression of specific sets of target genes in different tissues [146, 218, [226] [227] [228] [229] [230] [231] .
A variety of such new PPARg ligands with differential pharmacological affinities for PPARg have been reported in recent years. One of the first SPPARgMs that was tested, and which validated this idea, is FMOC-l-Leucine (F-lLeu), which separates insulin sensitivity from adipogenesis in vivo [232] .
The non-TZD-selective PPARg modulator (nTZDpa) was also shown to alter the conformational stability of the receptor when compared to TZDs. Chronic treatment of fat-fed C57BL/6J mice with nTZDpa improved hyperglycemia and hyperinsulinemia, and promoted reductions in weight gain and adipose depot size, without causing cardiac hypertrophy. In WAT, nTZDpa produced a different in vivo expression pattern of a panel of PPAR target genes when compared to a full agonist [227] . Similarly, a series of metabolically robust N-benzyl-indole partial PPARg agonists, with either a 3-benzoyl or 3-benzisoxazoyl moiety, also produced potent glucose reduction in db/db mice and attenuated increases in heart weight and BAT mass, which are typically observed in rodents upon treatment with PPARg full agonists [233, 234] . In addition, halofenate, one of the recently discovered SPPARgMs, displays the characteristics of an optimized modulator, retaining an insulin sensitization potential with minimal adipogenic activity in vitro and with less weight gain in vivo (ob/ob mouse and fa/fa Zucker rat models). At the molecular level, the partial agonism of halofenic acid may be explained in part by effective displacement of the corepressors NCoR and SMRT, coupled with inefficient recruitment of co-activators, such as p300, CBP, and TRAP 220 [235] . Further characterization of SPPARgMs will most likely yield novel agents for the treatment of type 2 diabetes, which are as effective as current pharmacological compounds but without their side effects. These findings should encourage mechanism-based screens [225] , which would capitalize on a still very incomplete knowledge of the ensemble of PPARg co-activators and co-repressors and their expression profile in tissues that are pivotal for PPARg action.
At this point, the emergence of novel potential therapeutic targets is worth mentioning, for the treatment of metabolic-related diseases, among which is the cofactor sirutin 1 (SIRT1), a protein lysine deacectylase. The human SIRT1 regulates several transcription factors that govern metabolism among which is PPARg. SIRT1 is induced by fasting in several tissues, such as the WAT where it represses PPARg activity thus decreasing the amount of fat storage. Its activation by resveratrol was shown to improve mitochondrial function and to protect against metabolic related diseases [236] [237] [238] [239] .
Conclusion
As described herein, the adipose tissue has been promoted within only a few years from a lipid storage bag to the most sophisticated, in terms of functions, and more importantly, in terms of mass, endocrine organ of the body. It participates in the control of energy balance in two ways: firstly by managing the energy depot of the body via the timely appropriate fine-tuned uptake, storage and release of lipids, and, secondly, by communicating with many organs via an incredibly rich array of endocrine signals that are emitted or received. With this in mind, it becomes clear why the functional integrity of this organ is primordial to whole-body homeostasis as a prerequisite for good health. Treatment of metabolic disorders through modulation of PPARg activity appears to have a promising future once knowledge has been acquired, enabling an activation/repression mechanism-based identification of PPAR isotype-selective modulators with the required characteristics. Ablation of the adipose tissue function by a selective full PPARg antagonist is obviously not a solution. Indeed, as discussed above, animal and human models of lipodystrophy, some of which were caused by complete or partial loss of PPARg activity, illustrate the deleterious and potentially dangerous outcome of such an approach. Supraphysiological stimulation of PPARg activity, such as that achieved by TZDs, triggers unwanted side effects. Based on present knowledge, the demanding path of highly selective SPPARgM identification with respect to functional outcome appears to be the most promising way forward in npg terms of potential therapeutic benefits. Such compounds may in fact open the route to preferred therapies for type 2 diabetes, obesity, and various manifestations of the metabolic syndrome.
